Prader-willi syndrome stories

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences is acquiring Soleno Therapeutics in a $2.9 billion deal to gain an approved medicine for a rare disease that causes insatiable hunger.